Delivering industry-leading performance with R&D Capabilities
Many forces are reshaping the way research and development must work in the future. Externally, payers and governments are taking active steps to reduce healthcare spend. They expect medicines to be safe, effective and good value for the money. By clearly demonstrating the value of our medicines, payers are more likely to pay for them, doctors to prescribe them and patients to access them. At the same time, science is rapidly advancing. We are embracing new technologies and incorporating new scientific approaches to give us increased confidence in the winning drug projects we are progressing. Our aim is to deliver a strong, competitive portfolio of new medicines that make a meaningful difference to patient health.
Enhanced skills and tools
We are giving teams more of the enhanced tools and skills they need to make the right decisions and deliver industry-leading performance. We call these skills our R&D Capabilities. By growing these capabilities, we will enhance our ability to develop effective, differentiated treatments drawing on cutting-edge approaches, standardised best practice, and increased capacity. With an investment of more than $200 million over five years, the company is committed to developing the resources and people to help reshape R&D performance.
This investment includes scientific collaborations, development of existing staff, recruitment of new talent, and new infrastructure - including informatics platforms.